Regulator Seizures and ER Minoxidil Trials Reshape UK Hair-Loss Market

Analysis

Enforcement is the week's hardest news: more than 65,000 illegal hair-loss products have been seized since 2021, according to reporting aimed at UK pharmacy teams ^[1]. For retailers and pharmacy counters, that is a clear signal that provenance and supply-chain checks on anti-hair-loss lines now carry reputational as well as regulatory weight ^[1].

On the clinical side, two separate trade reports point to extended-release oral minoxidil tablets showing potential for enhanced hair growth in androgenetic alopecia ^[2], with an oral ER minoxidil formulation demonstrating significant hair growth in men ^[3]. Prescribers and consumers are also being reminded that medication can work the other way: coverage this week examined which blood pressure medications cause hair loss and which alternatives may avoid it ^[4]. Chronic stress is being framed as "the hidden factor in hair thinning", with UK consumer press explaining why it causes hair loss and how to stop it ^[5]. Supplement claims remain contested, with dermatologists weighing in on whether biotin actually helps hair growth ^[6].

On shelf and in the feed, scalp care continues to sell through tools and serums. Vogue UK has rounded up the best scalp care tools to stimulate growth for readers worried about thinning hair ^[7], while Stylist published a first-person review of Kérastase's Genesis fortifying anti-hair-loss serum under the line "my hair is finally growing" ^[8]. Grooming media is also tackling wash-frequency confusion for men ^[9], and SoGlos has launched a hair-loss confidence series addressing the emotional side ^[10].